The “update should be important for determining EDP-235’s potential to tap into this large market,” noted a ROTH Capital Partners report.
Enanta Pharmaceuticals Inc.’s (ENTA:NASDAQ) antiviral EDP-235 “could be a best-in-class oral treatment for SARS-CoV-2, with the potential to circumvent viral rebound with novel dosing regimens,” reported ROTH Capital Partners analyst Zegbeh Jallah in a June 2 research note.
Jallah highlighted that the COVID-19 antiviral market represents a significant opportunity for Enanta and its clinical phase EDP-235. For example, an approved oral drug similar to EDP-235, Pfizer’s Paxlovid, is expected to generate $22 billion in sales this year, the company estimates.
Recent reports indicate some COVID patients treated with Paxlovid have experienced a recurrence of symptoms, and this raises concern that treatment with EDP-235 might also result in viral rebound, Jallah noted.
Such rebound could possibly be avoided with EDP-235, the analyst purported, simply by starting treatment later, specifically after peak viral loads, or giving it for a longer time period. He bases this theory on the results of a 2020 study by researchers at the Fred Hutchinson Cancer Research Center in Seattle, Wash.
Their analysis of data obtained on COVID patients showed that viral rebound happened when antiviral treatment was initiated before viral loads peaked. The researchers claim that when viral loads peak, it triggers an innate immune response in which infected or susceptible cells get removed. Yet when antiviral treatment is administered before viral loads spike, the response does not get activated fully and all suspect cells are not cleared out. This opens the door to viral rebound when viral loads peak post-treatment.
Get Our Free Metatrader 4 Indicators – Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
Get our Weekly Commitment of Traders Reports – See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Further, when the researchers looked at viral rebound with respect to five versus 10 days of COVID-inhibiting treatment, they discovered it only occurred with five days of treatment, not 10.
Enanta’s EDP-235 is currently in a Phase 1 clinical trial, but neither later treatment initiation nor longer treatment duration is being evaluated in it. It is unknown if Enanta will investigate either factor in the future.
The in-progress Phase 1 study is evaluating safety and pharmacokinetics. Results are expected shortly, sometime this month.
This “data update should be important for determining EDP-235’s potential to tap into this large market,” wrote Jallah.
The analyst expects, If the results are positive, big pharma to be interested in Enanta’s COVID inhibitor.
What EDP-235 already has going for it, Jallah wrote, is a longer half-life than Paxlovid and, potentially, increased potency, Jallah indicated. Accordingly, EDP-235 should have a longer therapeutic window than Paxlovid and should not need a subsequent booster treatment, as Paxlovid does (it is boosted with Ritonavir).
ROTH Capital Partners has a Buy rating and a $70 per share target price on Enanta, which is trading now at around $40.22 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for Roth Capital Partners, Enanta Pharmaceuticals Inc., June 2, 2022
ROTH makes a market in shares of Enanta Pharmaceuticals, Inc. and as such, buys and sells from customers on a principal basis.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from
sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request.
This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH.